Summary: Behavioral Health Business publishes an overview of the increasing popularity of psychedelics due largely to the promising psychedelic-assisted research results taking place. Author Laura Lovett highlights MAPS-sponsored psychedelic research and how “The industry is closely watching” MAPS’ research on MDMA-assisted therapy for PTSD. “In 2022, MAPS completed its second Phase 3 trial on MDMA to support the substance’s FDA approval,” writes Lovett. “Some industry insiders see this as the research that will lead to the first FDA clearance.”
